SASSARI, Italy & PRINCETON, N.J.--(BUSINESS WIRE)--Virostatics, srl, a privately-held pharmaceutical company focused on the discovery and development of combination therapeutics in HIV/AIDS, virology, and other chronic diseases, today announced it has initiated dosing of subjects in its five-arm, dose-ranging, proof of principle study VS411-C201: A randomized double-blind dose-finding multi-centre Phase IIa study with VS411 for HIV-1 infection. Investigators in four countries, Italy, Russia, Uganda, and Argentina, will enroll 60 patients into five randomized blinded arms containing varying dosages of enterically-coated didanosine and hydroxyurea, the two components of VS411.
